PLYMOUTH MEETING, Pa.–(BUSINESS WIRE)–Oct. 23, 2025– Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced preliminary results for Q3 2025, highlighted by the following:
- WAKIX® (pitolisant) franchise delivered net revenue of approximately $239 million in Q3 2025, representing 29% year-over-year revenue growth
- These results were driven by the highest ever quarterly increase in average number of patients of approximately 500 for the quarter, reaching 8,100 average patients in Q3 2025, accelerating the trajectory toward potential blockbuster status for WAKIX in narcolepsy
- The company is increasing its 2025 revenue guidance to $845-$865 million from the previous range of $820-$860 million
- Harmony to report full Q3 2025 earnings and host a conference call on November 4th
“Our robust performance this quarter highlights the continued strength of WAKIX and significant market opportunity that remains ahead. I am incredibly proud of our team’s focus and executional excellence, as we generated very strong results this quarter, positioning Harmony well for future growth,” said Jeffrey M. Dayno, M.D., President and CEO of Harmony Biosciences.
Harmony will report full third quarter 2025 financial results on Tuesday, November 4th, 2025, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on November 4th, 2025, at 8:30 a.m. ET to discuss the results.
To participate in the live call by phone, dial 800-274-8461 (domestic) or 203-518-9814 (international), and reference passcode HRMYQ325. The live and replay webcast of the call will be available on the investor page of our website at https://ir.harmonybiosciences.com/.